Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
TOKYO, July 27, 2017 — Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that it is winding down its Agensys research operations in Santa...
TOKYO – July 20, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) granted...
Osaka and Tokyo (Japan), July 7, 2017 – Maruho Co., Ltd (“Maruho”, Head Office: Osaka, Japan, President and CEO: Koichi Takagi) and Astellas Pharma Inc. (“Astellas”; Head Office: Tokyo,...
Tokyo, July 5, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been selected for the sixth consecutive year to be included in the...
Tokyo, June 30, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the submission of a supplemental New Drug Application (sNDA) to the...
TOKYO – June 20, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the launch of the second year of the Astellas C³ Prize, a...
TOKYO and NEW YORK, June 9, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today the amendment of the protocol...
Kyoto and Tokyo, June 5, 2017 - Kyoto University (President: Juichi Yamagiwa) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced the inauguration of...
Tokyo, June 1, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, ”Astellas”) today announced that it has committed to supporting the Global Health Innovative Technology Fund...
Tokyo, May 31, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the launch of a new global website. In accordance with the company Disclosure...
Tokyo, May 23, 2017 – Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) on International Day to End Obstetric Fistula, Astellas pledges its support to the Fistula...
Tokyo, May 19, 2017 -MSD K.K. (President: Jannie Oosthuizen; “MSD”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; “Astellas”) today announced that MSD has submitted an...
TOKYO – May 17, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today an update regarding the Company’s diverse oncology portfolio,...
Tokyo, May 17, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has completed the acquisition of Ogeda SA (formerly named...
Tokyo, May 11, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the discontinuation of ASP8273 treatment arm in the the late-stage...
Tokyo, May 11, 2016 - the Institute of Medical Science, the University of Tokyo (Tokyo, Dean: Yoshinori Murakami, “IMSUT”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko...
Tokyo, April 28, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) announced that Astellas and LTL Pharma Co., Ltd. (Representative Director, Chairman: Sansei Oka,...
Tokyo, March 22, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it launched a guanylate cyclase-C (GC-C) receptor agonist, LINZESS®...
CAMBRIDGE, Mass. and TOKYO, February 28, 2017 -- Affinivax, Inc. ("Affinivax") and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive worldwide license agreement...
Kyowa Pharmaceutical Industry Co., Ltd. (Head office: Yodogawa-ku, Osaka City, President and Representative Director: Ray Tsunoda, hereinafter called “Kyowa”) and Astellas Pharma Inc....
Tokyo, February 23, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that Astellas, Takeda Pharmaceutical Company Limited (President and CEO:...
Tokyo, January 31, 2017 – Astellas Pharma Inc. (“Astellas”; Head Office: Tokyo, President and CEO: Yoshihiko Hatanaka) today announced that it executed a license agreement with respect to an...
TOKYO & CAMBRIDGE, Mass., Jan. 30, 2017 — Astellas Pharma Inc. (TSE: 4503) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today top-line results indicating that the Phase III...
Tokyo, January 18, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced its participation in Access Accelerated, a global, multi-stakeholder...
Tokyo, January 12, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announces that it will launch the second phase of the ongoing campaign with CNN....
Tokyo, January 10, 2017 - Astellas Pharma Inc. (TSE:4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) announced that it exercised its right to terminate the agreement executed as of...
Tokyo, December 26, 2016 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) announced that it completed acquisition of its own shares, which was resolved by its Board of...
Tokyo, December 21, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has completed the acquisition of Ganymed Pharmaceuticals...
TOKYO (Dec. 20, 2016) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; General Manager and Representative Director: Mark Tennyson, “Amgen Astellas”) and Astellas Pharma Inc....
Tokyo, December 20, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) and Immunomic Therapeutics, Inc. (Founder & CEO: William Hearl, Ph.D., “Immunomic...
Tokyo, December 19, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it obtained a marketing approval for a guanylate cyclase-C (GC-C)...
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu), Astellas Pharma Inc. (HQ: Tokyo, Japan; President and CEO: Yoshihiko Hatanaka) and Daiichi Sankyo Co., Ltd. (HQ: Tokyo,...
TOKYO and CHERTSEY – 12 December, 2016: Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”), today announced that Astellas Pharma Europe Ltd. (“Astellas Pharma...
Tokyo, December 7, 2016 - Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it launched Kiklin® Granules 86.2% (generic name: bixalomer,...
Tokyo, November 30, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) is promoting its strategic goal “Pursuing Operational Excellence” and engaged...
Follow us
